Latest Administration News

TALi Digital has acquired the You Can Do It! Education program, integrating social-emotional learning into its digital health platform, supported by a $1.5 million equity raise to fund growth and technology reintegration.

Astron Corporation is set to redomicile from Hong Kong to Australia, establishing a new Australian parent company and simplifying shareholder engagement. This move aims to align governance with local standards and boost investor confidence.

Artrya Limited has submitted a pivotal FDA 510(k) application for its AI-powered Salix® Coronary Plaque module, aiming for clearance in Q3 2025 and a lucrative US commercial launch.

Talga Group’s Nunasvaara South graphite mine zoning plan process shifts to regional government after local deadline missed, advancing a key step in Sweden’s battery materials push.

Bubs Australia has submitted critical clinical trial data to the US FDA, marking a pivotal step toward permanent approval for its infant formulas in the US market.

Yowie Group Ltd has initiated an off-market takeover bid to acquire Keybridge Capital Limited, offering one Yowie share for each Keybridge share amid Keybridge's financial distress and administration history.

AdAlta Limited has successfully placed the remaining shortfall in its renounceable rights issue, raising a total of $1.3 million to advance its cellular immunotherapy pipeline. The company also addressed an administrative breach involving director share allocations, ensuring compliance with ASX rules.

Macarthur Minerals Limited has issued a replacement prospectus for a renounceable entitlement offer aiming to raise approximately AUD 2 million, fully underwritten by Gold Valley Yilgarn Pty Ltd. The offer includes free attaching options and supports the company’s exploration and operational funding needs.

Syntara Limited reports encouraging interim Phase 2 data for its drug SNT-5505 combined with ruxolitinib, demonstrating significant symptom relief and spleen volume reduction in myelofibrosis patients. The company plans to engage the FDA soon to discuss pivotal trial design.

FireFly Metals Ltd has announced a flow-through share offer aiming to raise approximately A$11.2 million, targeting Canadian investors to fund regional exploration drilling. This offer complements a broader capital raising strategy to advance development at the Ming Mine and other key projects.

Mesoblast reports positive FDA progress on accelerated approval for Revascor in ischemic heart failure and plans a pivotal trial to extend Ryoncil’s label to adults with graft versus host disease, while its US commercial launch outpaces expectations.

EVE Health Group has launched a $1.5 million capital raise alongside the acquisition of biotech firm Nextract, aiming to expand its footprint in health and pharmaceutical products focused on erectile dysfunction and period pain.